Based on the latest updates from the FDA, the suggested time frame to initiate hormone replacement therapy (HRT) to optimize treating disruptive symptoms caused by menopause is generally considered:

Hormone replacement therapy (HRT) is used to manage moderate to severe menopausal symptoms such as hot flashes, night sweats, and genitourinary syndrome of menopause. Current evidence and updated FDA-aligned guidance emphasize the importance of timing when initiating therapy because cardiovascular and thrombotic risks vary depending on how long after menopause treatment begins. The “timing hypothesis” supports starting HRT closer to menopause onset for maximum benefit and lower risk. This is a key principle in modern menopausal care. Rationale: A. Starting HRT before 65 years of age or within 5 years of menopause is narrower than current recommended guidance. While early initiation is beneficial, evidence supports a broader safe window of up to 10 years post-menopause or before age 60. Limiting to 5 years may exclude patients who could still benefit safely from therapy. B. 60 years of age or within 10 years of menopause is the currently supported guideline based on updated evidence and FDA-aligned recommendations. Hormone replacement therapy is most beneficial when started during this “window of opportunity,” where risks of cardiovascular disease, stroke, and thromboembolism are lower and symptom relief and bone protection benefits are maximized. C. Starting within 1 year of menopause or before age 50 is overly restrictive and not evidence-based as a general guideline. While earlier initiation can be appropriate, limiting therapy to such a narrow timeframe does not reflect current clinical recommendations and excludes many symptomatic patients who may still benefit safely within a broader window. D. HRT is not contraindicated in all menopausal patients. In fact, Hormone replacement therapy is an approved and effective treatment for vasomotor symptoms and prevention of bone loss in appropriately selected patients. Contraindicating all use is incorrect and ignores well-established benefits when therapy is individualized and appropriately timed.